Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
InMed Pharmaceuticals ( (INM) ) has issued an announcement.
On March 23, 2026, InMed Pharmaceuticals reported positive preclinical data showing its INM-901 candidate significantly reduced neuroinflammation in advanced 3D human brain organoid models of Alzheimer’s disease. The results, generated with Stem Pharm’s human neuro-immune organoid platform, closely mirror prior in vivo and ex vivo findings, reinforcing mechanistic translation from animal models to human-relevant systems.
The consistent, dose-dependent reduction of key pro-inflammatory markers such as IL-6 and IL-8 across multiple models is seen by the company as de-risking INM-901 ahead of first-in-human studies. InMed plans a U.S. regulatory pre-IND meeting in the third quarter of 2026 and is progressing IND-enabling pharmacology, toxicology and manufacturing work, aiming to move INM-901 into a Phase 1 clinical trial in 2027 as part of the emerging wave of neuroinflammation-focused Alzheimer’s therapies.
The most recent analyst rating on (INM) stock is a Hold with a $0.86 price target. To see the full list of analyst forecasts on InMed Pharmaceuticals stock, see the INM Stock Forecast page.
Spark’s Take on INM Stock
According to Spark, TipRanks’ AI Analyst, INM is a Neutral.
The score is driven primarily by weak financial quality (large losses and persistent cash burn, plus TTM inconsistency) and bearish technicals (negative MACD and price below longer-term averages). Corporate updates provide some pipeline upside, but valuation signals are not supportive given the non-meaningful P/E and no dividend.
To see Spark’s full report on INM stock, click here.
More about InMed Pharmaceuticals
InMed Pharmaceuticals Inc. is a pharmaceutical company developing proprietary, disease-modifying small-molecule drug candidates that target CB1 and CB2 receptors. The company’s pipeline spans three programs focused on Alzheimer’s disease, ocular conditions and dermatological indications, positioning it in niche segments of neurology and specialty care markets.
Average Trading Volume: 103,753
Technical Sentiment Signal: Sell
Current Market Cap: $2.39M
Learn more about INM stock on TipRanks’ Stock Analysis page.